Delving into the Latest Updates on Progenipoietin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ProGP-G, Progenipoietin-G

Target

FLT3 x G-CSF

Action-

Mechanism

FLT3 stimulants(Tyrosine-protein kinase receptor FLT3 stimulants), G-CSF stimulants(Granulocyte colony-stimulating factor stimulants), Immunostimulants

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Metastatic melanoma

Inactive Indication

Bone marrow depressionChemotherapy-induced myelosuppression

Originator Organization

Pfizer Inc.

Active Organization

University of Southern California

Inactive Organization

Pharmacia Corp.

Pfizer Inc.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Vaccine therapy plus filgrastim combined with a specific protein may be a more effective treatment for melanoma.
PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma that has been completely removed during surgery.

Start Date01 Jun 2000

Sponsor / Collaborator

University of Southern California

[+1]

100 Clinical Results associated with Progenipoietin

Login to view more data

100 Translational Medicine associated with Progenipoietin

Login to view more data

100 Patents (Medical) associated with Progenipoietin

Login to view more data

41

Literatures (Medical) associated with Progenipoietin

01 Dec 2024·Tissue and Cell

Alleviative effects of green-fabricated zinc oxide nanoparticles on acrylamide-induced oxidative and inflammatory reactions in the rat stomach via modulating gastric neuroactive substances and the MiR-27a-5p/ROS/NF-κB axis

Article

Author: Samak, Mai A. ; Alosaimi, Manal E. ; Albaqami, Amirah ; Alotaibi, Badriyah S. ; El-Shetry, Eman S. ; El-Shetry, Eman S ; Alotaibi, Badriyah S ; Mohamed, Amany Abdel-Rahman ; Metwally, Mohamed M.M. ; Alosaimi, Manal E ; Alosaimi, Manal ; Samak, Mai A ; Metwally, Mohamed M M ; Mawkili, Wedad ; Khamis, Tarek ; Abd-Elhakim, Yasmina M ; ElAshmouny, Naira ; Alsharif, Ghadi ; Abd-Elhakim, Yasmina M. ; Dahran, Naief

Little is known about the effects of acrylamide (AMD) on the stomach. So, this study evaluated the effect of oral AMD exposure (20 mg/kg b.wt) on oxidative status, apoptotic, and inflammatory reactions in rat's stomach for 60 days. To explore novel targets of AMD toxicity, a more detailed molecular and immune-expression study was performed. Besides, the possible protective effect of green synthesized zinc oxide nanoparticles (G-ZNP) (10 mg/kg b.wt) was explored. The results revealed that AMD significantly provoked oxidative and lipid peroxidative damage of the stomach in terms of increased ROS and MDA but reduced SOD, CAT, GSH, and GSH/GSSG. Additionally, the stomachs of AMD-exposed rats showed a significant increment of PGE2 but reduced NO. Histopathologically, AMD induced a significant increase in PAS stain and the immunoexpression of iNOS and NF-κB in the glandular stomach. A significant upregulation of CART, VACHT, EGFR, caspase-3, NOS-1, and miR-27a-5p was evident in the stomach of the AMD group. Yet, G-ZNP oral dosing significantly rescued the AMD-induced oxidative damage, apoptotic reaction, inflammatory effect, and altered miR-27a-5p and gene expressions in the stomach. Conclusively, these findings demonstrated the efficacy of G-ZNP in protecting against the harmful impacts of acrylamide on stomach tissues.

23 Jan 2023·Inorganic Chemistry

Composite with a Glassy Nonporous Coordination Polymer Enhances Gas Adsorption Selectivity

Article

Author: Yagi, Ichizo ; Zheng, Xin ; Kato, Masaru ; Nakamura, Takayoshi ; Matsumura, Daiju ; Takahashi, Kiyonori ; Uemura, Yohei ; Noro, Shin-ichiro

A glass-crystal composite (g-NCP/PCP), comprising a glassy nonporous coordination polymer (g-NCP) and a crystalline porous coordination polymer (PCP)/metal-organic framework, was synthesized by using a melt-quenched method. Compared to that of the PCP itself, g-NCP/PCP has an enhanced gas adsorption selectivity. The results should stimulate further studies of the chemistry of g-NCP/PCP glass-crystal composites.

01 Mar 2022·Annals of HematologyQ3 · MEDICINE

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease

Q3 · MEDICINE

Article

Author: Fradette, Caroline ; Tsang, Yu Chung ; Rozova, Anna ; Soulières, Denis ; Tricta, Fernando ; Mercier-Ross, Jules

Abstract Patients with sickle cell disease (SCD) who undergo repeated blood transfusions often develop iron overload. Deferiprone (Ferriprox®) is an oral iron chelator indicated for the treatment of transfusional iron overload due to thalassemia syndromes and has been recently approved as a treatment for iron overload in adult and pediatric patients with SCD and other anemias. The present study aims to characterize the pharmacokinetic (PK) profile of deferiprone (DFP) in adult subjects with SCD. In this phase I, open-label study, subjects with SCD were administered a single 1500 mg dose of DFP. Blood and urine samples were collected for PK assessments of DFP and its main metabolite, deferiprone 3-O-glucuronide (DFP-G). Eight subjects were enrolled and completed the study. Following drug administration, serum levels of DFP and DFP-G rose to maximum concentrations at 1.0 and 2.8 h post-dose, respectively. The half-lives of DFP and DFP-G were 1.5 and 1.6 h, respectively. The majority of administered drug was metabolized and excreted as DFP-G, with less than 4% excreted unchanged in urine up to 10 h post-dose. Subjects received a safety assessment 7 (± 3) days post-dose. Two subjects reported mild adverse events unrelated to the study drug, and no other safety concerns were reported. The PK profile of DFP in SCD subjects is consistent with previous reports in healthy adult volunteers, suggesting no special dosing adjustments are indicated for this population. These findings provide valuable insight for treating iron overload in patients with SCD, who have limited chelation therapy treatment options (trial registration number: NCT01835496, date of registration: April 19, 2013).

100 Deals associated with Progenipoietin

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic melanoma	Phase 1	United States	University of Southern California	01 Apr 2003
Bone marrow depression	Discovery	United States	Pharmacia Corp.	-
Chemotherapy-induced myelosuppression	Discovery	-	Pfizer Inc.	-
Neoplasms	Discovery	United States	Pharmacia Corp.	-